Keywords: cv, save, 75m, via, job, cuts, palo
CV to save $75M via job and R&D cuts
Article | 04 June 2007
Palo Alto, California, USA-based CV Therapeutics is lowering its annual operating expense guidance by approximately $75.0 million, and now estimates that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
